MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER

For a long time, chemotherapy remained the main treatment option for metastatic urothelial carcinoma (mUC). Over the past year, there have been revolutionary changes associated with the approval of five new drugs aimed at blocking the interaction between the surface protein of T-lymphocytes PD-1 and...

Full description

Saved in:
Bibliographic Details
Main Authors: R. A. Gafanov, S. V. Garmash, I. B. Kravtsov, S. V. Fastovets
Format: Artigo
Language:Russo
Published: QUASAR, LLC 2018-03-01
Series:Issledovaniâ i Praktika v Medicine
Subjects:
bladder cancer
pd-1
pd-l1
immunotherapy
atezolizumab
nivolumab
pembrolizumab
avelumab
durvalumab
Online Access:https://www.rpmj.ru/rpmj/article/view/246
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items